1. Home
  2. CSR vs CDNA Comparison

CSR vs CDNA Comparison

Compare CSR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$59.78

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$17.37

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSR
CDNA
Founded
1970
1998
Country
United States
United States
Employees
349
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
CSR
CDNA
Price
$59.78
$17.37
Analyst Decision
Hold
Buy
Analyst Count
7
7
Target Price
$70.50
$27.33
AVG Volume (30 Days)
96.3K
520.8K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
5.17%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
$2.45
$15.37
Revenue Next Year
$1.84
$11.23
P/E Ratio
$62.27
N/A
Revenue Growth
N/A
18.93
52 Week Low
$52.76
$10.96
52 Week High
$69.15
$21.49

Technical Indicators

Market Signals
Indicator
CSR
CDNA
Relative Strength Index (RSI) 32.65 41.71
Support Level $57.19 $16.99
Resistance Level $60.67 $20.94
Average True Range (ATR) 1.62 0.67
MACD -0.21 -0.06
Stochastic Oscillator 6.90 37.09

Price Performance

Historical Comparison
CSR
CDNA

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: